Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2952293 | 0.78 | DYRK1A (0.43) | NOS1DYRK1AHSD17B10ALDH1A1PARP1 | |
| SCHEMBL9940746 | 0.74 | NOS1 (0.55) | NOS1DYRK1AHSD17B10ALDH1A1MEN1 | |
| SCHEMBL20296481 | 0.73 | GRIN2D (0.37) | HSD17B10PARP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL31306288 | 0.73 | AHR (0.44) | ALDH1A1PARP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL15900336 | 0.73 | AHR (0.44) | ALDH1A1PARP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL601322 | 0.70 | NOS1 (0.56) | NOS1DYRK1AHSD17B10ALDH1A1PARP1 | |
| SCHEMBL19176400 | 0.70 | ALDH1A1 (0.39) | HSD17B10ALDH1A1PARP1PRKCIPDE4B | |
| SCHEMBL25184055 | 0.70 | ALDH1A1 (0.44) | DYRK1AHSD17B10ALDH1A1PARP1PRKCI | |
| SCHEMBL30032497 | 0.69 | ALDH1A1 (0.41) | HSD17B10ALDH1A1PARP1PRKCIPDE4B | |
| SCHEMBL20296556 | 0.69 | GRIN2D (0.37) | DYRK1AALDH1A1PARP1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106795147-B | Cyclopropyl fused thiazine-2-amine compounds as beta-secretase inhibitors and methods of use | 美国安进公司 | 2020-09-22 | — | — | CN | disclosed |
| US-20170267673-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267673-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267673-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2017-09-21 | — | — | US | disclosed |
| EP-3177618-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2017-06-14 | — | — | EP | disclosed |
| US-9550762-B2 | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550762-B2 | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550762-B2 | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160046618-A1 | Cyclopropyl Fused Thiazin-2-Amine Compounds as Beta-Secretase Inhibitors and Methods of Use | AMGEN INC. (US) | 2016-02-18 | — | — | US | disclosed |
| WO-2016022724-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016022724-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267673-A1 | CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | NOS1 1510/4885DYRK1A 2293/4885HSD17B10 1803/4885 |
| US-20160046618-A1 | Cyclopropyl Fused Thiazin-2-Amine Compounds as Beta-Secretase Inhibitors and Methods of Use | BACE1, BACE2, APP | NOS1 1510/4885DYRK1A 2293/4885HSD17B10 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.